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Abstract: Chimeric antigen receptor (CAR) redirected T cells are efficacious in the treatment of
leukemia/lymphoma, however, showed less capacities in eliminating solid tumors which is thought
to be partly due to the lack of cytokine support in the tumor lesion. In order to deliver supportive
cytokines, we took advantage of the inherent ability of mesenchymal stem cells (MSCs) to actively
migrate to tumor sites and engineered MSCs to release both IL7 and IL12 to promote homeostatic
expansion and Th1 polarization. There is a mutual interaction between engineered MSCs and CAR T
cells; in presence of CAR T cell released IFN-γ and TNF-α, chronic inflammatory Th2 MSCs shifted
towards a Th17/Th1 pattern with IL2 and IL15 release that mutually activated CAR T cells with
extended persistence, amplification, killing and protection from activation induced cell death. MSCs
releasing IL7 and IL12 were superior over non-modified MSCs in supporting the CAR T cell response
and improved the anti-tumor attack in a transplant tumor model. Data demonstrate the first use of
genetically modified MSCs as vehicles to deliver immuno-modulatory proteins to the tumor tissue in
order to improve the efficacy of CAR T cells in the treatment of solid malignancies.
Keywords: CAR T cells; MSC; adoptive cell therapy; genetic immunotherapy; IL7; IL12
1. Introduction
Adoptive cell therapy with chimeric antigen receptor (CAR) modified T cells induces lasting
remissions of B cell leukemia and lymphomas [1,2], however, the efficacy of CAR T cell therapy
against solid tumors is so far poor and T cells rapidly enter exhaustion [3]. Tremendous efforts are
currently made to prolong the CAR T cell response in the hostile tumor tissue, particularly, the chronic
inflammatory environment mediates T cell repression and exhaustion. To overcome the situation, we
reason to shift the cytokine environment towards an acute immune response in order to sustain and
prolong a CAR T cell response which will finally result in an improved control of solid tumor lesions.
In order to deliver biologically active proteins to the tumor tissue, we thought to use mesenchymal
stem cells (MSCs) as vehicles due to several reasons; MSCs are major components of the tumor stroma
of different tissue origin [4] and are key players in orchestrating the tumor bed with respect to the
cellular composition and regulation. This is particularly due to the tremendous plasticity of MSCs
to differentiate into different types of stromal cells [5] and their capability to secrete a variety of
chemokines and cytokines [6,7]. In contrast to their physiological function in wound healing and tissue
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repair [8], in cancer tissues MSCs initiate and sustain an inflammatory milieu that promotes tumor
progression [9]. This process is moreover sustained by cancer cells that reprogram tumor resident
MSCs to release a variety of factors that sustain cancer cell growth and invasion [10]. Moreover, MSCs
exhibit an inherent ability to home towards tumors of various tissue origin including carcinomas
of breast, lung, pancreas, and ovary. The tumor homing capacity was used to deliver therapeutic
products to the tumor site by applying genetically engineered MSCs [11–17]. In particular, the capacity
to actively migrate into the tumor tissue and the ease to engineer the cells by viral vectors makes
MSCs attractive for delivering transgenic immune modulators in order to shift the tumor bed from
an inhibitory to an immune stimulatory environment [18]. For therapeutic purposes, human MSCs
moreover have the advantage that the cells are invisible to allo-recognition which allows using these
cells as an allogeneic “off-the-shelf” cell product.
We addressed whether bone marrow derived MSCs sustain a CAR T cell attack against colorectal
cancer. MSCs were engineered to release both IL7 and IL12 in order to shift the chronic inflammatory
profile in the tumor tissue into a more favorite one for an acute CAR T cell response. IL7 and
IL12 modified MSCs (termed apceth-301) improved the CAR T cell activation as judged by cytokine
production and cytolytic activities, increased CAR T cell amplification, and decreased activation
induced cell death (AICD); the elimination of adenocarcinoma cells by CAR T cells was improved in a
xenograft mouse model. To the best of our knowledge, this is the first report to use genetically modified
MSCs to modulate the cytokine milieu in the tumor stroma in order to sustain a CAR T cell attack.
2. Materials and Methods
2.1. Cell lines and Reagents
HEK293T cells are human embryonic kidney cells that express the SV40 large T antigen [19].
The colon carcinoma cell lines Colo320 (ATCC CCL 220.1) and LS174T (ATCC CL-188) were obtained
from ATCC, Rockville, MD, USA. The anti-CD3 monoclonal antibody (mAb) OKT3, anti-CD28 mAb
15E8 and CAR-specific anti-idiotypic mAb BW2064/36 were purified by affinity chromatography from
OKT3 hybridoma (ATCC CRL 8001), 15E8 hybridoma (kindly provided by Dr. R. van Lier, Red Cross
Central Blood Bank, Amsterdam, The Netherlands), and BW2064/36 [20] hybridoma supernatants,
respectively. The PE-conjugated F(ab’)2 goat anti-human IgG antibody was purchased from Southern
Biotechnology. Fluorochrome-conjugated anti-CD3 mAb was purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany). Respective fluorochrome-conjugated isotype controls were purchased from BD
Biosciences (San Diego, CA, USA). Matched antibody pairs for capture and detection of human IFN-γ
were purchased from BD Biosciences. Recombinant IL2 was obtained from Endogen (Woburn, MA,
USA). Immunofluorescence was analyzed using a FACS-CantoTM cytofluorometer equipped with the
Diva software (Version 6.0, Becton Dickinson, Mountain View, CA, USA).
2.2. Preparation of Human T Cells
Peripheral blood lymphocytes were obtained from healthy donors by Ficoll density centrifugation.
T cells were initially activated by OKT3 and 15E8 mAbs (100 ng/mL each) and IL2 (500 U/mL) and
further cultivated in the presence of IL2 (500 U/mL).
2.3. Isolation and Generation of Human Mesenchymal Stem Cells (MSC)
MSC were isolated from bone marrow of healthy donors. Bone marrow was seeded into
5-layer culture stacks (Corning) and cultivated in apceth’s proprietary xeno-free Medium Bio-1.
Once MSC colonies became visible, MSC were harvested and cryopreserved (representing the MSC
stock). Cryopreservation medium consisted of human serum albumin (Baxter), Hydroxyethyl starch
(Fresenius Kabi, Bad Homburg, Germany), and 10% (v/v) DMSO. Transduced and native MSC batches
were obtained from these stocks. Cryopreserved MSC stocks were taken into culture in Bio-1 medium
at a density of 1000 to 5000 cells/cm2. After 3–5 days MSCs were harvested for transduction with a
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retroviral vector encoding human IL7 and IL12 or IL7 alone. MSCs were mixed with viral vectors at
a MOI between 2 and 15 and seeded in 5-layer stacks. Three days after transduction, medium was
removed and replaced by Bio-1 medium containing puromycin (3 µg/mL). Cells were selected for 3–5
days and further cultivated in standard Bio-1 Medium until cryopreservation. MSCs underwent 3–5
passages before being cryopreserved.
2.4. Generation of γ-Retroviral Vector to Engineer MSC
The used retroviral vectors are based on the retroviral SIN-vector pSERS11 [21]. Cloning was
performed by the “In-Fusion recombination Kit” (Clonetech, Mountain View, CA, USA) which allows
cloning by recombination. From the parental vector, a deletion was introduced between the 3′
untranslated region and the wPRE element to remove the internal promoter and original transgene. In
the next step the human EFS promoter was introduced. Additionally, an encephalomyocarditis
virus internal ribosome entry site followed by the puromycin resistance gene pac (puromycin
N-acetyltransferase) was introduced down-stream of the promoter. To generate the IL7/IL12 construct,
the human IL7 and IL12 genes, separated by a P2A site, were introduced between the promoter and
the IRES site. To generate the IL7 construct the human IL7 was introduced between the promoter and
the IRES site. Schematic vector maps are shown in Supplementary Figure S1. Vectors were generated
by transient transfection of 293T cells as previously described [22].
2.5. Chimeric Antigen Receptors (CARs)
Engineering of CARs with specificity for the carcinoembryonic antigen (CEA) with the modified
CD28-CD3ζ signalling domain [23] as well as the retroviral modification of T cells were previously
described in detail [20,24,25].
2.6. T Cell Modification
Human peripheral blood T cells were retrovirally engineered for CAR expression [26]. T cells
were stimulated and transduced on day 2 or 3 by γ-retrovirus containing supernatants or by co-culture
with virus producing 293T cells as described [27]. Retroviruses were produced by 293T cells upon
transient transfection with the DNA of the GALV encoding and the gag/pol encoding helper plasmid,
and the plasmid encoding the respective CAR. CAR expression was monitored by flow cytometry
using an antibody against the common extracellular IgG1 Fc domain.
2.7. Flow Cytometry
For flow cytometric analysis, CAR T cells were stained with fluorochrome-labeled antibodies
specific for human IgG1 and CD3, respectively, and recorded by a FACSCanto II flow cytometer
equipped with the FACSDiva software (Version 6.0, BD Bioscience, San Jose, CA, USA). MSC
characterization is reported in Supplementary Materials and Methods.
2.8. Activation of CAR T Cells
CAR T cells (2.5 × 104 cells/well) were co-cultivated for 48 h in 96-well round bottom plates with
tumor cells (each 2.5–5× 104 cells/well) and non-modified or cytokine-modified MSCs (5× 103 cells/well).
Specific cytotoxicity of CAR T cells against antigen-positive target cells was monitored by an XTT based
colorimetric assay [28] using the “Cell Proliferation Kit II” (Roche Diagnostics, Mannheim, Germany).
Viability of tumor cells was calculated as mean values of six wells containing only tumor cells subtracted
by the mean background level of wells containing medium only. Non-specific formation of formazane
due to the presence of T cells was determined from triplicate wells containing T cells in the same
number as in the corresponding experimental wells. The number of viable tumor cells in experimental
wells was calculated as follows: viability (%) = (OD (experimental wells–corresponding number of T
cells))/(OD (tumor cells + MSC without T cells)–OD (medium)) × 100. Cytotoxicity (%) was defined
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as 100–viability (%). In another set of experiments, 96-well plates were coated with 4 µg/mL of the
CAR specific anti-idiotypic mAb BW2064/36 or PBS for control. CAR T cells were CFSE (Thermo
Fisher Scientific, Meerbusch, Germany) labeled according to manufacturer’s recommendations and
co-cultivated (2.5 × 104/well) with unmodified or cytokine modified MSCs (5 × 103–2 × 104/well) for
5 days. Cells were recovered and stained with anti-human IgG-PE and 7-AAD (Sigma-Aldrich, St.
Louis, MO, USA) to identify live and dead CAR T cells and the number of cycling cells was determined
by flow cytometry.
2.9. ELISA
IFN-γ and IL10 in culture supernatants were monitored by ELISA by binding to the solid
phase anti-IFN-γ and IL10 capture antibody (each 1 µg/mL), respectively, and detection by the
biotinylated anti-IFN-γ or anti-IL10 detection antibody (0.5 µg/mL), respectively. The reaction product
was visualized by a peroxidase-streptavidin conjugate (1:10,000) and ABTS (Roche Diagnostics,
Basel, Switzerland).
2.10. Multiplex Immunoassay
Secretion of cytokines and chemokines by MSCs and CAR T cells co-cultivated with MSCs and
tumor cells was analyzed by a 43-parameter multiplex immunoassay (ProcartaPlex®; eBioscience,
Frankfurt am Main, Germany), according to the manufacturer’s recommendations. Briefly, MSCs
(25,000 cells/mL) were cultivated for 72 h in presence or absence of exogenous IFN-γ (10 ng/mL)
and TNF-α (10 ng/mL). CAR T cells were co-cultivated with CEA+ tumor cells and non-modified or
cytokine modified MSCs. The assays were performed in quadruples and supernatants of two wells
were pooled and subjected to multiplex analysis. Data are expressed as means of duplicates.
2.11. CAR T Cell Mediated Suppression of Tumor Growth
NSG mice (Charles River, Sulzfeld, Germany) (5–12 animals/group) were subcutaneously
inoculated with LS174T colorectal cancer cells (2.5 × 106 cells/animal), CAR T cells (2 × 106 cells/animal)
and non-modified or cytokine modified MSCs (4 × 105 cells/animal). T cells without CAR served as
control. Tumor volumes were recorded every 2–3 days. When tumors reached a volume of > 1500 mm3
mice were sacrificed. Survival and tumor-free survival of mice were recorded. Experiments were
approved by the local ethics committee.
2.12. Statistics
Experimental results from independent representative experiments are reported as mean values ±
standard deviation (SD). Significance analyses was performed by the two-sided Student’s T test and
log rank test using Microsoft Excel and Graphpad Prism, respectively.
3. Results
3.1. CAR T Cells Modulate the Activity of MSCs
Due to their tumor homing capacity tissues MSCs, with or without genetic engineering, are
potential vehicles to deliver transgenic cell products that therapeutically modify the tumor tissue and
improve an anti-tumor CAR T cell response. We isolated MSCs from the bone marrow of healthy donors
and defined the cells according to the International Society for Cellular Therapy specifications [29]
(Figure S2). MSCs were characterized to express CD73, CD90, and CD105 and to lack CD34 and CD45.
The procedure of MSC preparation and ex vivo amplification was robust and reproducible since bone
marrow derived MSCs from three different donors secreted a similar pattern of cytokines and growth
factors with only minor quantitative differences into the supernatant as revealed by 43-parameter
multiplex analysis (Figure 1).
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described in Materials and Methods. Data were grouped and mean values ± SD were determined. 
In order to alter the cytokine profile in the tumor tissue we modified the MSCs by genetic 
engineering to release IL7, IL12, and both IL7 and IL12, respectively (Figure 2). A representative flow 
cytometric analysis of genetically modified MSCs is shown in Figure S2B. The transduction procedure 
itself did not impair the ability of MSCs to differentiate into osteoblasts and adipocytes as shown in 
Figure S2C. Moreover, genetically modified MSCs with release of transgenic IL7 and IL12 secreted 
basically a similar pattern of cytokines as the parental MSCs (Figure 2).  
Figure 1. Mesenchymal stem cells (MSCs) from different donors secrete a similar pattern of cytokines
and growth factors. Bo e marrow derived MSCs (25,000/mL) of three donors were cultivated for 72
h. Supernatants ere collected and subjected in duplicates to 43-parameter multiplex analysis as
described in Materials and Methods. Data were grouped and mean values ± SD were determined.
In order to alter the cytokine profile in the tumor tissue we modified the MSCs by genetic
engineering to r lease IL7, IL12, and both IL7 and IL12, ectively (Figure 2). A representative flow
cytometric analysis of genetically modified MSCs is sho n in Figure S2B. The transduction procedure
itself did not impair the ability of MSCs to differentiate into osteoblasts and adipocytes as shown in
Figure S2C. Moreover, genetically modified MSCs with release of transgenic IL7 and IL12 secreted
basically a similar pattern of cytokines as the parental MSCs (Figure 2).Cells 2020, 9, x 6 of 16 
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pattern of MSCs will be altered by T cell secreted pro-inflammatory cytokines. MSCs and IL7/12 
engineered MSCs from two donors were cultured in the presence of added IFN-γ and TNF-α. As 
summarized in Figure 2, IFN-γ and TNF-α induced in MSCs up-regulation of secretion of several 
pro-inflammatory cytokines including IL6 and IL23 indicating an enforced inflammatory reaction. 
This is not due to transgenic IL7 and IL12 since unmodified MSCs altered the pattern of cytokine 
secretion in a similar fashion.  
To address how MSCs impact a tumor specific CAR T cell attack, we engineered T cells with a 
second generation CD28Δ-ζ CAR that is deficient in IL2 secretion due to a mutation in the lck binding 
domain of CD28 [30]. Upon transduction, the CAR was expressed in about 30–40% of T cells (Figure 
S3). Anti-CEA CAR T cells were co-cultured with CEA+ LS174T cells for 48 h and the supernatants 
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engagement of tumor cells, CAR T cells secreted high amounts of pro-inflammatory cytokines like 
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Figure 2. Non-modified MSCs and IL7/IL12 engineered MSCs have a similar pattern of secreted
cytokines that is altered in presence of TNF-α and IFN-γ. MSCs of two donors were transduced to
secrete IL7 and IL12, respectively, and cultivated for 72 h (25,000/mL) in presence and absence of added
TNF-α (10 ng/mL) and IFN-γ (10 ng/ L), respective . Supernatants were collected and subjected in
duplicates to 43-parameter multiplex analysis as described in Materials and Methods.
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When in proximity to activated CAR T cells, MSCs are facing a panel of pro-inflammatory cytokines
like IFN-γ and TNF-α secreted by CAR T cells. We asked whether the cytokine secretion pattern of
MSCs will be altered by T cell secreted pro-inflammatory cytokines. MSCs and IL7/12 engineered MSCs
from two donors were cultured in the presence of added IFN-γ and TNF-α. As summarized in Figure 2,
IFN-γ and TNF-α induced in MSCs up-regulation of secretion of several pro-inflammatory cytokines
including IL6 and IL23 indicating an enforced inflammatory reaction. This is not due to transgenic IL7
and IL12 since unmodified MSCs altered the pattern of cytokine secretion in a similar fashion.
To address how MSCs impact a tumor specific CAR T cell attack, we engineered T cells with
a second generation CD28∆-ζ CAR that is deficient in IL2 secretion due to a mutation in the lck
binding domain of CD28 [30]. Upon transduction, the CAR was expressed in about 30–40% of T
cells (Figure S3). Anti-CEA CAR T cells were co-cultured with CEA+ LS174T cells for 48 h and the
supernatants were tested for cytokines and growth factors by 43-parameter multiplex analysis (Figure 3).
Upon engagement of tumor cells, CAR T cells secreted high amounts of pro-inflammatory cytokines
like IFN-γ, IL23, and TNF-α (Figure 3A). Adding MSCs resulted in enhanced the production of
pro-inflammatory cytokines during a CAR T cell attack (Figure 3B) likely due to the activation of MSCs
through CAR T cell derived TNF-α and IFN-γ (cf. Figure 2). In presence of IFN-γ and TNF-α, MSCs
released IL2 and IL15 (Figure 3C) that, on the other hand, mutually activated CAR T cells indicated
by high IL6 and IL23 release which enforced a pro-inflammatory Th17 response. We concluded that
CAR T cells and MSCs, with or without transgenic IL7 and IL12, cooperate in up-regulating Th17
cytokines. Increased IL7 and IL12 in presence of transduced MSCs was accompanied by IL10 release
during antigen-specific activation of CAR T cells (Figure 3D). This is in accordance with a previous
report that IL12 enhanced IL10 secretion by T cells [31]. Taken together, CAR T cells and MSCs can
mutually cooperate in enhancing a Th17 inflammatory anti-tumor response; IL7 and IL12 producing
MSCs shift the T cell response to a Th1 like anti-tumor response.
3.2. MSCs Improved Antigen-Specific Amplification and Survival of CAR T Cells
By altering the cytokine secretion pattern, MSCs may impact proliferation and persistence of
CAR T cells upon antigen engagement. MSCs were co-cultured with CFSE-labeled CAR T cells in
the presence of the solid phase mAb BW2064 that is an anti-idiotypic mAb against the CAR binding
domain and acts as surrogate antigen. MSCs increased amplification of CAR T cells when co-incubated
at a ratio of 1:4 MSC:CAR T cells (Figure 4A); higher MSC numbers inhibited activation induced cell
death (AICD) (Figure 4B). We concluded that added MSCs improve CAR driven T cell amplification
and survival in vitro. The number of CAR T cells even more increased in the presence of IL7 and IL12
secreting MSCs (Figure 5A). This is due to increased numbers of cycling CAR T cells (Figure 5B) and a
decreased frequency of AICD. AICD of CAR T cells was reduced even at low numbers of IL7/IL12
modified MSCs which was less the case in presence of non-modified MSCs (Figure 5C).
3.3. IL7 and IL12 Engineered MSCs Modulate the Cytotoxic CAR T Cell Attack
To address whether MSCs modulate the cytotoxic CAR T cell attack against antigen-positive
tumor cells we co-cultivated anti-CEA CAR T cells with CEA+ LS174T and CEA− Colo320 tumor
cells in the presence of MSCs and recorded CAR mediated target cell lysis (Figure 6). CAR T cell
mediated elimination of CEA+ target cells was increased in the presence of IL7 and IL12 releasing
MSCs compared with non-modified MSCs. Increased target cell lysis was due to IL12 because IL7
releasing MSCs without IL12 did not enhance CAR mediated cytotoxicity. Notably, non-modified
MSCs also enhanced the anti-tumor cell reactivity of CAR T cells and non-modified T cells.
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Figure 3. Chimeric antigen receptor (CAR) triggered cytokine secretion pattern of CAR T cells is
specifically altered by MSCs. (A) Anti-carcinoembryonic antigen (CEA) CAR T cells were co-cultivated
in 96-well plates (2.5 × 104 cells/well) in quadruples with LS174T tumor cells (2.5 × 104 cells/well),
respectively. After 48 h supernatants were recovered and supernatants of 2 adjacent wells were pooled
an subjected to 43-p rameter multiplex analysis as described in Materials and Methods. Mean value
of duplicates were determined and data were displayed as heat map. (B–D) Anti-CEA CAR T cells
were co-cultivated with LS174T cancer cells as described above in presence of wt or IL7/IL12 modified
MSCs (5 × 103 cells/well) and subjected to 43-parameter multiplex analysis as described above. The
number of secreted cytokines and growth factors was determined, and x-fold secretion compared to
release of cytokines in presence of CAR T cells and tumor cells alon was calculated and presented
as heat map (B). Cytokine secretion was dependent on the presence of MSC (C) or IL7/12 producing
MSCs (D), data indicate mean values of duplicates.
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Figure 4. MSCs modulate antigen driven CAR T cell amplification. Anti-CEA CAR T cells were CFSE
labeled and co-cultivated (2.5 × 104 cells/well) together with MSCs in 96-well plates that were coated
ith the R specific anti-idiotypic mAb BW2064 (4 µg/mL) or PBS for control. After 5 days cells were
recovered, CAR T cells stained with an anti-IgG-PE antibody to detect the CAR and analyzed by flow
cytometry. Dead cells were identified by 7-AAD staining (1 µg/mL) and the number of proliferating
cells was determined by CFSE dilution. (A, B) CAR T cell proliferation in presence of MSCs (each
5000 cells/well) of three different donors. (A) Histograms of a typical experiment. (B) Su mary of
CAR T cell proliferation in presence of MSC. (C) CAR T cell proliferation and cell death in presence
of increasing numbers of MSCs (5000–20,000 cells/well). Values represent the mean of replicates +/−
standard deviation (SD). Significant differences were calculated by Student’s T test; * p < 0.01.
3.4. IL7 and IL12 Secreting MSCs Sustain the Overall Anti-Tumor Response in a Transplant Tumor Model
Despite the high tumor tropism of engineered MSC [32], the majority of intravenously applied
MSCs in the xenogenic mouse disappeared rapidly from the circulation during the lung passage [33]
and those that persist in the circulation required a long time period for accumulation in the tumor
tissue. We therefore addressed whether IL7/IL12 modified MSCs improve the CAR T cell anti-cancer
cell attack by local application of MSCs and CAR T cells in a similar fashion as described previously by
others [34–37]. We co-injected NSG mice with anti-CEA CAR T cells, IL7/IL12 modified MSCs, and
CEA+ tumor cells. T cells without CAR and non-modified MSCs without IL7 and IL12 secretion served
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as controls. CAR T cells alone suppressed tumor formation and improved the survival (Figure 7A). T
cells without CAR also took benefit from IL7 and IL12 secreting MSCs resulting in prolonged survival;
this was not the case when co-inoculating non-modified MSCs (Figure 7B). The effect is due to MSC
released IL7 and IL12 since non-modified MSCs had no impact on the anti-tumor activity of CAR T
cells (Figure 7C).
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MSCs without IL12 did not enhance CAR mediated cytotoxicity. Notably, non-modified MSCs also 
enhanced the anti-tumor cell reactivity of CAR T cells and non-modified T cells. 
Figure 5. IL7 and IL12 secreting MSCs enhance CAR driven T cell proliferation and reduce
activation induced cell death (AICD). Anti-CEA CAR T cells were CFSE labeled and co-cultivated
(2.5 × 104 cells/well) with or without non-modified or IL7/IL12-modified MSCs in 96-well plates
(5000 cells/well) that were coated with the anti-idiotypic mAb BW2064 (4 µg/mL) for CAR engagement
or with PBS for control. After 5 d ys cells were recovered, stained with an anti-IgG-PE antibody to
detect the CAR and analyzed by flow cytometry. The number of proliferating T cells was determined by
CFSE dilution, dead cells were identified by 7-AAD staining (1 µg/mL) and the number of proliferating
cells was determined. (A) CAR T cell proliferation in presence or absence of MSCs; (b,c) number of
rapidly cycling CAR T cells within the observation period; (B) flow cytometric histograms of a typical
experiment after stimulation with the anti-idiotypic mAb, (C) summary of rapidly cycling CAR T cells.
(D) AICD of CAR T cells in pr sence or absence of MSCs. Values represent the mean of replicates
+/− standard deviation (SD). Sign ficant differ nces were calculated y Student’s T test. p < 0.05, n.s.,
not significant.
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Figure 7. IL7 and IL12 secreting MSCs sup ort a ti-tumor respo se in vivo. NSG mice (5–12
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CAR T cells or non-modified T cells (2 × 106/mouse) in presence or absence of non-modified or IL7 and
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growth of individual animals; red line represents mean values. (b–d) Kaplan Meier plots of data with
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4. Discussion
We here report on the use of bone marrow derived MSCs engineered with IL7 and IL12 to sustain
a CAR T cell attack against colorectal cancer. The concept takes benefit of the unique capacity of MSCs
to migrate to and to infiltrate into solid tumors [18] and, upon genetic modification, to produce and
deliver transgenic cytokines to the tumor.
MSC engineering with a retroviral vector encoding the production and release of IL7 and IL12 was
efficient and without altering the cell phenotype. The use of these cytokines is based on the rationale
that IL7 promotes the homeostatic expansion and sustains memory cell function of T cells [38], both
crucial for the success of CAR T cell therapy. IL12 induces a protective Th1 response and prevents
Th2 polarization of T cells [39] and, moreover, attracts and activates an innate immune response to
eliminate those cancer cells that are invisible to CAR T cells [40]. Both cytokines were not produced
by CAR T cells or MSCs but impact the CAR T cell response. Screening of the panel of cytokines
released during a CAR T cell anti-tumor cell attack in the presence of engineered MSCs revealed that
the chronic inflammatory Th2 response of non-modified MSCs shifted towards a Th17/Th1 pattern that
is supportive for a T cell anti-tumor response. In particular, there is a CAR T cell mediated pattern
of cytokines that was up-regulated by non-modified and IL7/IL12 engineered MSCs. The release of
anti-tumorigenic cytokines like IFN-γ, IL6, IL23, IL18, and TNF-α was enhanced in the presence of
IL7/IL12 engineered MSCs; these cytokines will likely shift the pro-tumorigenic chronic inflammatory
situation to a more anti-tumorigenic acute inflammation capable to sustain an anti-tumor response by
CAR T cells and potentially other infiltrating adaptive and innate immune cells [41].
While MSCs are pivotal regulatory constituents of the tumor stroma by promoting tumor
progression and invasion [4,42], our data revealed that there can be a mutual cross-talk between
MSCs and anti-tumor T cells with substantial impact on the overall tumor control. The pattern of
cytokines released by non-modified MSCs resembles a chronic inflammatory Th2 reaction capable
to support tumor growth rather than a T cell anti-tumor attack. During a CAR T cell attack through
released IFN-γ and TNF-α, the MSCs shift towards a more acute inflammatory response resulting in
an improved anti-tumor reactivity and persistence of CAR T cells. While non-modified MSCs enhance
a Th17 dominated pro-inflammatory immune response, IL7 and IL12 engineered MSCs shifted the
CAR T cell response towards Th1 inflammation with extended CAR T cell persistence indicated by
robust killing, T cell amplification, and protection from activation induced cell death. In a transplanted
xenograft tumor model, IL7/IL12 engineered MSCs boosted the anti-tumor activity of CAR T cells
while non-modified MSCs do not have the effect.
The impact of MSCs on immune regulatory functions of CAR T cells is complex and depends on
the MSC to CAR T cell ratio. In the presence of low numbers of non-modified MSCs the CAR driven T
cell proliferation is improved whereas the inhibition of AICD requires higher numbers of MSCs. The
situation is different in the presence of IL7 and IL12 engineered MSCs due to the increased levels of
acute pro-inflammatory cytokines that drive Th1 polarization. IL12 enhanced antigen-specific CAR T
cell proliferation, reduced AICD and enhanced target cell lysis which was not observed in the presence
of IL7 MSCs. The presence of IL12, however, induced also IL10 secretion in CAR T cells that may have
double impact on an immune attack against cancer cells: antigen presentation of APC may be inhibited
but on the other hand IL10 will modify cancer promoting chronic inflammation. Whereas the role
of IL10 on cancer growth may be ambiguous [43,44] we expect an overall beneficial impact of IL7/12
engineered MSC on a CAR T cell attack.
Upon tumor infiltration, MSCs arrange themselves in close proximity with tumor cells and
vasculature [45], making them ideal vehicles for the delivery of cytokines that are picked up by
infiltrating immune cells including CAR T cells. There is an ongoing discussion whether the inherent
MSCs homing and retention capabilities are sufficient for a lasting therapeutic effect; engineering
MSCs with a truncated, non-signaling CAR was applied in order to increase tumor affinity [46] and to
improve delivery of therapeutic proteins [47,48]. MSCs were modified for targeting by transduction
with a targeting domain like a chimeric receptor targeting EGFRvIII [45,49] and GD2 [46]. MSCs
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were engineered with both to deliver TRAIL and to specifically recognize GD2 through a truncated
anti-GD2 CAR in order to improve their retention in the targeted GD2 positive tumors like glioblastoma,
sarcomas and neuroblastoma [46]. These modified MSCs mediate an improved anti-tumor response
with a prolonged cell-to-cell interaction and thereby more effectively delivering TRAIL. The first
step to use engineered MSCs to support a T cell anti-tumor response was most recently reported by
Szoor et al. [50] who engineered MSCs to release a bispecific T cell engager and to provide CD80
and 4-1BB costimulation. The T cells themselves, however, were not modified in order to redirect
their cytolytic activities in a pre-defined fashion. In that situation the MSCs needed to provide both
costimuli CD80 and 4-1BB in order to induce T cells for antigen-dependent IL2 release and tumor cell
killing. In our concept, however, the redirected T cells obtained co-stimulation by the CAR and were
supported in prolonging their response through IL7/IL12 delivered by the MSCs.
Whereas modified MSCs clearly improved the anti-cancer cell activities of CAR T cells in vitro
but also induces anti-tumor reactivity in CAR− lymphocytes, the situation in vivo seems to be more
complex. In a xenograft model, CAR T cells efficiently suppressed tumor growth in the presence of
non-modified MSCs that could only slightly be improved in the presence of IL7/IL12 engineered MSCs.
The same IL7/IL12 MSCs enhanced the allogeneic response of T cells independently of the CAR implying
that IL7/IL12 engineered MSCs booster the specific T cell response and initiate antigen-independent
anti-tumor activities. This may be due to high secretion of IL22 and IL23 by MSCs. These cytokines
were recently described to recruit and activate CD56+ cells for an innate immune response [51–53]
and were secreted independently of engineering IL7/IL12 secretion and may activate non-specific
cytotoxicity against cancer cells that is further boosted by IL12 of engineered MSC. A recent report
demonstrated a local effect of IL7/12 engineered MSC on tumor infiltrating cells as well as a systemic
effect on circulating lymphocytes resulting in up-regulation of activation markers [37]. Accordingly,
a CAR T cell attack and acquisition of antigen-independent cytotoxicity will synergistically benefit
from both effects. Hereby, IL7 will improve persistence of CAR T cells and other cytotoxic lymphocytes
in the periphery and the tumor tissue whereas IL12 will directly boost anti-tumor cytotoxicity as
demonstrated in this report.
The acquisition of antigen-independent anti-tumor activities of CAR T cells is of particular
relevance when eliminating tumors with a heterogeneous pattern of targetable antigens. This holds for
the majority of solid tumor lesions that harbor cancer cells lacking the antigen and rendering those
cancer cells invisible to CAR T cells which potentially give rise to tumor relapse after initially successful
tumor reduction. The IL7/IL12 MSC and CAR T cell-based approach combines both strategies and
delivers cytokines that sustain both a redirected antigen-specific and an antigen-independent immune
cell response. MSCs engineered to release IL7 and IL12 as “of-the-shelf cell therapy additives” will help
to establish a pro-inflammatory response that prolongs the T cell anti-tumor attack and successfully
counteracts repression through the tumor environment.
5. Conclusions
MSCs engineered to release IL7 and IL12 shift the chronic inflammatory Th2 profile of the tumor
microenvironment into a more favorite Th17/Th1 profile with an improved and prolonged anti-tumor
CAR T cell response. Data demonstrate the use of genetically modified MSCs as vehicles to modulate
the inflammatory tumor microenvironment and to establish a mutual stimulatory interaction between
modified MSCs and CAR T cells during an anti-tumor attack.
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